LSV Asset Management Increases Stock Holdings in Embecta Corp. $EMBC

LSV Asset Management lifted its stake in shares of Embecta Corp. (NASDAQ:EMBC) by 92.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 552,582 shares of the company’s stock after buying an additional 265,482 shares during the period. LSV Asset Management owned about 0.93% of Embecta worth $6,565,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its stake in shares of Embecta by 9.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,708 shares of the company’s stock valued at $148,000 after buying an additional 1,050 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Embecta by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock valued at $209,000 after buying an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after buying an additional 1,159 shares during the period. A&I Financial Services LLC raised its stake in shares of Embecta by 2.5% in the fourth quarter. A&I Financial Services LLC now owns 63,542 shares of the company’s stock valued at $755,000 after buying an additional 1,556 shares during the period. Finally, Larson Financial Group LLC raised its stake in shares of Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after buying an additional 1,574 shares during the period. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Price Performance

Embecta stock opened at $3.32 on Wednesday. Embecta Corp. has a 52 week low of $2.77 and a 52 week high of $15.55. The business has a 50-day simple moving average of $7.22 and a 200 day simple moving average of $10.09. The stock has a market cap of $196.98 million, a price-to-earnings ratio of 1.75 and a beta of 1.09.

Embecta (NASDAQ:EMBC) last posted its earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The business had revenue of $221.80 million for the quarter, compared to analysts’ expectations of $235.67 million. During the same quarter in the previous year, the firm earned $0.70 earnings per share. Embecta’s quarterly revenue was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, research analysts anticipate that Embecta Corp. will post 1.62 earnings per share for the current year.

Embecta Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Thursday, May 28th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 1.2%. The ex-dividend date is Thursday, May 28th. Embecta’s payout ratio is presently 31.58%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on EMBC shares. Mizuho lowered their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Bank of America decreased their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Wall Street Zen lowered Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings lowered Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, May 6th. Finally, BTIG Research lowered Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Strong Sell” and a consensus target price of $11.00.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.